Posted On: 07/07/2014 8:34:19 AM
Post# of 30066
Amarantus Announces Three Data Presentations Related to the Company's LymPro Diagnostic Test at the Alzheimer's Association International Conference (AAIC)
Download PDF
SAN FRANCISCO and GENEVA, July 7, 2014 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that analytical performance, clinical performance and 6-year longitudinal data related to the Company's LymPro Test® will be presented at the Alzheimer's Association International Conference (AAIC), held at the Bella Center in Copenhagen, Denmark, July 12-17, 2014.
"We are pleased to be presenting data on three critical aspects of LymPro's diagnostic profile," said Gerald E. Commissiong, President & CEO of Amarantus. "It is critical to properly position LymPro within the scientific community as we advance towards commercialization. We believe this data will provide the basis for pharmaceutical companies to use LymPro initially as a surrogate marker in their trials and for Key Opinion Leaders to add LymPro as a tool in their diagnostic paradigm. These key constituents will be critical for LymPro's initial market adoption."
Poster Presentation Details
Date: July 14 2014
Location: Exhibit Hall (Bella Center Convention Center)
Poster Session Time: 11:45a.m. - 2:15 p.m.
Session Type: AAIC Poster Presentation
Proposal Number: 45402
Presentation Title: Employing Lymphocyte Proliferation as a means to Asses Cell Cycle Dys-regulation in Cognitively Impaired Subjects: Clinical Performance of the LymPro Assay
Poster Number: P2-389
Date: July 15, 2014
Location: Exhibit Hall (Bella Center Convention Center)
Poster Session Time: 11:45 a.m. – 2:15 p.m.
Session Type: AAIC Poster Presentation
Proposal Number: 45240
Presentation Title: Retrospective Analysis of Clinical Prognosis of Subjects from a 2008 study using the LymPro assay
Poster Number: P3-118
Date: July 15, 2014
Location: Exhibit Hall (Bella Center Convention Center)
Poster Session Time: 11:45 a.m. – 2:15p.m.
Session Type: AAIC
oster Presentation
Proposal Number: 45398
Presentation Title: Employing Lymphocyte Proliferation as a means to Asses Cell Cycle Dys-regulation in Cognitively Impaired Subjects: Analytical Performance of the LymPro Assay
Poster Number: P3-117
About LymPro Test
The Lymphocyte Proliferation Test (LymPro Test ®) is a diagnostic blood test that measures the ability of peripheral blood lymphocytes to withstand an external stimulation inducing them to enter the cell cycle. It is hypothesized that certain diseases are the result of a compromised cellular machinery that leads to abhorrent cell cycle re-entry by neurons. The inventive step for LymPro involves using peripheral blood lymphocytes (PBLs) as a surrogate for neuronal cell function, suggesting a common immune-based relationship between PBLs and neurons in the brain. LymPro Test ® is currently being developed as a diagnostic blood test for Alzheimer's disease and is being evaluated as a diagnostic blood test for Traumatic Brain injury and Chronic Traumatic Encephalopathy.
Download PDF
SAN FRANCISCO and GENEVA, July 7, 2014 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that analytical performance, clinical performance and 6-year longitudinal data related to the Company's LymPro Test® will be presented at the Alzheimer's Association International Conference (AAIC), held at the Bella Center in Copenhagen, Denmark, July 12-17, 2014.
"We are pleased to be presenting data on three critical aspects of LymPro's diagnostic profile," said Gerald E. Commissiong, President & CEO of Amarantus. "It is critical to properly position LymPro within the scientific community as we advance towards commercialization. We believe this data will provide the basis for pharmaceutical companies to use LymPro initially as a surrogate marker in their trials and for Key Opinion Leaders to add LymPro as a tool in their diagnostic paradigm. These key constituents will be critical for LymPro's initial market adoption."
Poster Presentation Details
Date: July 14 2014
Location: Exhibit Hall (Bella Center Convention Center)
Poster Session Time: 11:45a.m. - 2:15 p.m.
Session Type: AAIC Poster Presentation
Proposal Number: 45402
Presentation Title: Employing Lymphocyte Proliferation as a means to Asses Cell Cycle Dys-regulation in Cognitively Impaired Subjects: Clinical Performance of the LymPro Assay
Poster Number: P2-389
Date: July 15, 2014
Location: Exhibit Hall (Bella Center Convention Center)
Poster Session Time: 11:45 a.m. – 2:15 p.m.
Session Type: AAIC Poster Presentation
Proposal Number: 45240
Presentation Title: Retrospective Analysis of Clinical Prognosis of Subjects from a 2008 study using the LymPro assay
Poster Number: P3-118
Date: July 15, 2014
Location: Exhibit Hall (Bella Center Convention Center)
Poster Session Time: 11:45 a.m. – 2:15p.m.
Session Type: AAIC
oster Presentation Proposal Number: 45398
Presentation Title: Employing Lymphocyte Proliferation as a means to Asses Cell Cycle Dys-regulation in Cognitively Impaired Subjects: Analytical Performance of the LymPro Assay
Poster Number: P3-117
About LymPro Test
The Lymphocyte Proliferation Test (LymPro Test ®) is a diagnostic blood test that measures the ability of peripheral blood lymphocytes to withstand an external stimulation inducing them to enter the cell cycle. It is hypothesized that certain diseases are the result of a compromised cellular machinery that leads to abhorrent cell cycle re-entry by neurons. The inventive step for LymPro involves using peripheral blood lymphocytes (PBLs) as a surrogate for neuronal cell function, suggesting a common immune-based relationship between PBLs and neurons in the brain. LymPro Test ® is currently being developed as a diagnostic blood test for Alzheimer's disease and is being evaluated as a diagnostic blood test for Traumatic Brain injury and Chronic Traumatic Encephalopathy.
(0)
(0)
